Thermo Fisher Scientific Apolipoprotein B Polyclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

1:2,000 - 1:10,000

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Goat / IgG

Class

Polyclonal

Type

Antibody

Immunogen

apoLipoprotein Type B was isolated from human plasma by density gradient centrifugation followed by HPLC purification. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:Apolipoprotein B,uniProtId:P04114-1,ncbiNodeId:9606,antigenRange:1-4563,antigenLength:4563,antigenImageFileName:600-101-111_Apolipoprotein_B_P04114-1_Goat.svg,antigenImageFileNamePDP:600-101-111_Apolipoprotein_B_P04114-1_Goat_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Affinity chromatography

Storage buffer

0.125M sodium borate, pH 8, with 0.005M EDTA, 0.075M NaCl

Contains

0.01% sodium azide

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. Glycerol (1:1) may be added for added stability.

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

This product is stable at 4°C as an undiluted liquid.

Dilute only prior to immediate use.

For extended storage mix with an equal volume of glycerol, aliquot contents and freeze at -20°C or below.

Target Information

Apolipoprotein B (apo B) in human plasma is a major protein of low density lipoproteins (LDL) with a molecular mass of approximately 260-500 kDa. Apolipoprotein B binds to specific receptors on cell membranes and is involved in removal of LDL and very low density lipoprotein (VLDL) cholesterol from circulation. Low-density lipoprotein (LDL) is the carrier protein for cholesterol in the blood. LDL binds to its receptor on the capillary walls and thereby mediates the uptake and clearance of cholesterol from the circulation. In atherosclerotic lesions oxidatively modified LDL is found and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptor A and CD36. Oxidized LDL may be a marker of atherosclerosis but the precise changes in oxidized LDL are not well described. MDA-oxidized LDL appear to be different from LDL oxidized by other means. Apolipoprotein B is mostly synthesized in the liver, and is a major apolipoprotein of very low density, intermediate density and low density lipoproteins (LDL) as well as being a major component of lipoprotein (a). Apolipoprotein B is a ligand for the LDL receptor and elevated levels are associated with premature atherosclerosis. Normal plasma apolipoprotein B levels are around 800mg/L. Apolipoprotein B occurs in plasma as two main isoforms, apoB-48 and apoB-100. The intestinal and the hepatic forms of Apolipoprotein B are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in the Apolipoprotein B gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective Apolipoprotein B, diseases affecting plasma cholesterol and Apolipoprotein B levels.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.